^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

TP-1454

i
Other names: TP-1454
Associations
Company:
Sumitomo Pharma
Drug class:
Pyruvate kinase-M2 activator
Related drugs:
Associations
6ms
Phase 1 Study of Oral TP-1454 (clinicaltrials.gov)
P1, N=31, Active, not recruiting, Sumitomo Pharma America, Inc. | Recruiting --> Active, not recruiting | N=50 --> 31 | Trial completion date: Dec 2025 --> Oct 2024 | Trial primary completion date: Sep 2025 --> Oct 2024
Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
|
CD4 (CD4 Molecule)
|
TP-1454
over1year
Phase 1 Study of Oral TP-1454 (clinicaltrials.gov)
P1, N=50, Recruiting, Sumitomo Pharma Oncology, Inc. | Active, not recruiting --> Recruiting | Trial completion date: Oct 2023 --> Dec 2025 | Trial primary completion date: Apr 2023 --> Sep 2025
Enrollment open • Trial completion date • Trial primary completion date
|
CD4 (CD4 Molecule)
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • TP-1454
almost2years
Phase 1 Study of Oral TP-1454 (clinicaltrials.gov)
P1, N=44, Active, not recruiting, Sumitomo Pharma Oncology, Inc. | Recruiting --> Active, not recruiting
Enrollment closed • Combination therapy
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability)
|
PD-L1 expression • MSI-H/dMMR
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • TP-1454
almost3years
Phase 1 Study of Oral TP-1454 (clinicaltrials.gov)
P1, N=44, Recruiting, Sumitomo Dainippon Pharma Oncology, Inc | Trial completion date: Dec 2022 --> Oct 2023 | Trial primary completion date: Nov 2022 --> Apr 2023
Trial completion date • Trial primary completion date • Combination therapy
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability)
|
PD-L1 expression • MSI-H/dMMR
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • TP-1454
over3years
[VIRTUAL] Pkm2 activation modulates the tumor-immune microenvironment and enhances response to checkpoint inhibitors in preclinical solid tumor models (AACR 2021)
We are currently exploring the effect of TP-1454 treatment on O-GlcNac of Foxp3 and its stability in HEK293 cells, to support the link between PKM2 activation and stabilization of Foxp3.TP-1454 effects on tumor-specific immunity were validated using tumor rechallenge studies. The results of a tumor rechallenge study will be presented using murine MC38 or RENCA xenograft models that are treated with TP-1454 and I/O combination therapies that exhibited a complete response (CR) and were re-implanted.These preclinical studies indicate a unique mechanism modulating tumor metabolism and the TME to improve the response of cancer patients to immunotherapy.
Preclinical • Checkpoint inhibition
|
CD4 (CD4 Molecule) • FOXP3 (Forkhead Box P3)
|
TP-1454